| 期刊論文| 1. | Gaede, P.、Lund-Andersen, H.、Parving, H. H.、Pedersen, O.(2008)。Effect of a multifactorial intervention on mortality in type 2 diabetes。N Engl J Med，358，580-591。   | | 2. | Nathan, D. M.、Buse, J. B.、Davidson, M. B.、Heine, R. J.、Holman, R. R.、Sherwin, R.(2006)。Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes。Diabetologia，49，1711-1721。 | | 3. | Butler, A. E.、Janson, J.、Bonner-Weir, S.、Ritzel, R.、Rizza, R. A.、Butler, P. C.(2003)。Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes。Diabetes，52，102-110。 | | 4. | 呂金盈(20111200)。腸泌素在第二型糖尿病治療的角色。內科學誌，22(6)，401-408。 延伸查詢 | | 5. | Htike, Z. Z.、Khunti, K.、Davies, M.(2012)。A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes。Diabetes Ther，3，1-16。 | | 6. | Cvetkovic, R. S.、Plosker, G. L.(2007)。Exenatide: a review of its use in patients with type 2 diabetes mellitus。Drugs，67，935-954。 | | 7. | Buse, J. B.、Henry, R. R.、Han, J.、Kim, D. D.、Fineman, M. S.、Baron, A. D.(2004)。Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes。Diabetes Care，27，2628-2635。 | | 8. | De Fronzo, R. A.、Ratner, R. E.、Han, J.、Kim, D. D.、Fineman, M. S.、Baron, A. D.(2005)。Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes。Diabetes Care，28，1092-1100。 | | 9. | Kendall, D. M.、Riddle, M. C.、Rosenstock, J.、Zhuang, D.、Kim, D. D.、Fineman, M. S.、Baron, A. D.(2005)。Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea。Diabetes Care，28，1083-1091。 | | 10. | Rosenstock, J.、Shenouda, S. K.、Bergenstal, R. M.、Buse, J. B.、Glass, L. C.、Heilmann, C. R.(2012)。Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes。Diabetes Care，35，955-958。 | | 11. | American Diabetes Association(2013)。Standards of medical care in diabetes--2013。Diabetes Care，36(Suppl. 1)，S11-S66。 | | 12. | Garber, A. J.、Abrahamson, M. J.、Barzilay, J. I.、Blonde, L.、Bloomgarden, Z. T.、Bush, M. A.(2013)。American association of clinical endocrinologists ‘ comprehensive diabetes management algorithm 2013 consensus statement--executive summary。Endocr Pract，19，536-557。 | | 13. | Bamett, A. H.、Burger, J.、Johns, D.、Brodows, R.、Kendall, D. M.、Roberts, A.(2007)。Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial。Clin Ther，29，2333-2348。 | | 14. | Heine, R. J.、Van Gaal, L. F.、Johns, D.、Mihm, M. J.、Widel, M. H.、Brodows, R. G.(2005)。Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial。Ann Intern Med，143，559-569。 | | 15. | Anderson, S. L.、Trujillo, J. M.、McDermott, M.、Saseen, J. J.(2012)。Determining predictors of response to exenatide in type 2 diabetes。J Am Pharm Assoc，52，466-471。 | | 16. | Klonoff, D. C.、Buse, J. B.、Nielsen, L. L.、Guan, X.、Bowlus, C. L.、Holcombe, J. H.(2008)。Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years。Curr Med Res Opin.，24，275-286。 | | 17. | Blonde, L.、Klein, E. J.、Han, J.、Zhang, B.、Mac, S. M.、Poon, T. H.(2006)。Interim analysis of the effects of exenatide treatment on Ale, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes。Diabetes Obes Metab，8，436-447。 | | 18. | Ratner, R. E.、Maggs, D.、Nielsen, L. L.、Stonehouse, A. H.、Poon, T.、Zhang, B.(2006)。Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus。Diabetes Obes Metab，8，419-428。 | | 19. | Elashoff, M.、Matveyenko, A. V.、Gier, B.、Elashoff, R.、Butler, P. C.(2011)。Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies。Gastroenterology，141，150-156。 | | 20. | Weise, W. J.、Sivanandy, M. S.、Block, C. A.、Comi, R. J.(2009)。Exenatide-associated ischemic renal failure。Diabetes Care，32，22-23。 | | 21. | Gutzwiller, J. P.、Tschopp, S.、Bock, A.、Zehnder, C. E.、Huber, A. R.、Kreyenbuehl, M.。Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men。J Clin Endocrinol Metab，89，3055-3061。 | 其他| 1. | Global diabetes plan 2011-2021，http://www.idf.org/sites/default/files/Global_Diabetes_Plan_Final.pdf， 2012/12/18。 | | 2. | MedWatch The FDA safety information and adverse event reporting program: safety information--byetta (exenatide); 2007，http://www.fda.gov/Safety/MedWatch/Safetylnformation/SafetyAlertsforHumanMedicalProducts/ucm150839.htm， 2013/09/09。 | | 3. | MedWatch The FDA safety information and adverse event reporting program: safety information--byetta (exenatide) --renal failure; 2013，www.fda.gov/Safety/MedWatch/Safetylnformation/SafetyAlertsforHumanMedicalProducts/ucml88703.htm， 2013/09/20。 | |